Journal of Clinical Oncology
Articles in this Issue
Molecular imaging as a tool to predict patient outcomes in advanced HER2-low breast cancer on trastuzumab deruxtecan (T-DXd): The FHERAD trial.
1052 Background: The DESTINY-Breast04 trial demonstrated for the first time that trastuzumab deruxtecan (T-DXd), a HER2-ta...
Comprehensive genomic landscape of early-onset colorectal cancer: A comparative analysis with average-onset metastatic colorectal cancer in a next-generation sequencing cohort of 1,892 patients.
e15596 Background: The incidence of early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before t...
Tumor board–based multi-agent LLMs with guideline retrieval and consensus deliberation: Implications for hepatocellular carcinoma clinical reasoning.
e16015 Background: Hepatocellular carcinoma (HCC), requires multidisciplinary decision-making across specialities. Multidi...
Rural-urban survival differences in advanced non–small cell lung cancer in the modern treatment era: A SEER-based analysis.
e13735 Background: Rural-urban disparities in cancer outcomes are well documented; however, whether recent therapeutic adv...
Comparison of survival after chemotherapy vs no chemotherapy in elderly patients with pancreatic cancer.
e16442 Background: Pancreatic cancer disproportionately affects older adults, yet real-world outcomes associated with chem...
Net clinical value of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer: Integrating efficacy heterogeneity and treatment burden.
e12659 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) improve pathological complete response (pCR) rates in e...
Characterization of inavolisib-associated hyperglycemia in metastatic hormone receptor–positive (HR+) breast cancer.
e13055 Background: Inavolisib + palbociclib + fulvestrant is approved in patients with HR+, HER2-, PIK...
Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.
1004 Background: Clinical guidelines recommend Dmab 120 mg every 4 weeks (Q4W) for patients (pts) with bone metastases. Wh...
Improving dermatologic surveillance in solid organ transplant recipients through a navigation program.
e21554 Background: Solid organ transplant recipients (SOTRs) face markedly elevated skin cancer risk, with cutaneous squam...
Adenoma detection following screening colonoscopy and stool-based colorectal cancer screening tests with follow-up colonoscopy: A systematic and network meta-analysis.
e15647 Background: Colorectal cancer (CRC) screening offers an opportunity to prevent invasive disease by detecting and re...
Extracellular and immune matrix signature of interstitial fluid as mediator of pathological characteristics of colorectal cancer.
e15653 Background: The interstitial fluid (ISF) in tumor microenvironment harbors abundant proteins and metabolites critic...
Determinants of skin cancer prevention and early detection behaviors in Syria: A cross-sectional survey.
e22557 Background: Skin cancer prevention and early detection depend on sun-protective behaviors, skin self-examination, a...
A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC).
3534 Background: Maintenance therapy with capecitabine (Cap) is widely recommended to unresectable mCRC patients (pts). Fr...
Correlates of alcohol-related cancer risk awareness in U.S. adults.
e22675 Background: Alcohol consumption is a modifiable risk factor for multiple malignancies, yet public understanding of...
Peritumoral stiffness as a novel noninvasive biomarker: Predicting TACE response in intermediate-stage hepatocellular carcinoma via 2D-shear wave elastography.
4143 Background: Intermediate-stage hepatocellular carcinoma (HCC) demonstrates considerable biological and clinical heter...
Nimotuzumab combined with paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma: A prospective, multicenter, double-blind, randomized controlled clinical study.
4055 Background: Chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) is limited due to the lack of effecti...
Influence of racial, socioeconomic, and tumor characteristics on potential years of life lost (PYLL) in renal cell carcinoma: A population-based SEER analysis.
e16532 Background: Traditional survival metrics may underestimate the burden of premature death. Potential years of life l...
Impact of broadening trial eligibility criteria on the inclusion of patients infected with HIV in cancer clinical trials.
1548 Background: In October 2017, an ASCO, Friends of Cancer Research (FoCR), and US FDA (ASCO/FoCR/FDA) task force recomm...
Real-world toxicity of bispecific antibodies versus CAR-T cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.
7033 Background: CAR-T cell therapy and bispecific antibodies (BsAbs) have transformed treatment of relapsed or refractory...
Anthracycline-free vs anthracycline-containing dual anti-HER2 neoadjuvant therapy: Real-world outcomes.
e12676 Background: The incremental value of anthracyclines with dual anti-HER2 neoadjuvant therapy (NAT) for early HER2+ b...
Breast cancer incidence and mortality in LGBTQ+ populations compared with cisgender heterosexual individuals: A comparative epidemiologic synthesis.
1118 Background: Breast cancer incidence and mortality by sexual orientation and gender identity remain poorly characteriz...
Use of spatial multiomics to identify endosomal trafficking and S100A8/A9, and fibronectin-driven immune remodeling programs with T-DXd resistance in breast cancer brain metastases.
e15199 Background: Trastuzumab deruxtecan (T-DXd) has transformed the treatment of breast cancer brain metastases (BCBM)....
Features of gene copy number variation regulating mitochondrial function in endometrial cancer patients with type 2 diabetes mellitus.
e17630 Background: Endometrial cancer (EC) holds a leading position among oncogynecological diseases. Type 2 diabetes mell...
Real-world evidence for comprehensive genomic profiling in myeloid malignancies: Changes in detection and clinical impact.
e18636 Background: Myeloid malignancies are characterized by marked genomic heterogeneity, where accurate and timely ident...
TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
TPS4263 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a 5-year survival rate of < 5%. Approved tr...